Things You Should Know

What does PCOS metabolic health actually mean?

Polycystic ovary syndrome (PCOS) is a common endocrine condition that combines reproductive signs with metabolic changes. Metabolic health refers to how the body handles glucose, insulin, blood lipids, blood pressure, and body fat distribution. In PCOS, these systems often overlap. Available human evidence, including systematic reviews and meta-analyses, shows that PCOS is associated with higher rates of insulin resistance, dyslipidemia, hypertension, and type 2 diabetes.

This matters for longevity because metabolic strain can accumulate over decades, even when symptoms first appear in adolescence or early adulthood. Research suggests the pattern is not identical in every person. PCOS is heterogeneous, meaning one person may have marked hyperandrogenism, while another may show milder reproductive signs but more metabolic burden.

Essential terms help frame the topic. Insulin resistance (IR) means body tissues respond less effectively to insulin. Hyperandrogenism (HA) means excess androgen activity, measured clinically or biochemically. Dyslipidemia means an unfavorable lipid pattern, often involving triglycerides and high-density lipoprotein cholesterol (HDL-C). Human studies indicate these traits often cluster, but obesity is not required. Lean women with PCOS may also show metabolic risk, which is why PCOS is better understood as a lifespan metabolic-reproductive condition rather than only an infertility diagnosis.

Why is PCOS relevant to long-term health and aging?

PCOS matters in aging because its metabolic effects may begin early and remain relevant well beyond the reproductive years. Human longitudinal studies and meta-analyses suggest that women with PCOS have higher long-term risks of type 2 diabetes, hypertension, and some adverse lipid patterns than women without PCOS. One meta-analysis of longitudinal human studies also found a higher risk of non-fatal cerebrovascular events, while evidence for coronary events and fatal cardiovascular disease was less consistent.

A key concept is that long-term health depends on both current symptoms and cumulative exposure. Repeated glucose dysregulation, abdominal adiposity, and vascular stress may influence later cardiometabolic health. In a human follow-up cohort over about 10 years, glucose concentrations rose and beta-cell function declined, while insulin sensitivity changed little. That pattern suggests metabolic reserve may weaken over time in some women with PCOS.

The evidence is not absolute. Not every outcome worsens in every study, and some lipid markers or event outcomes show null findings. Still, the overall evidence base supports seeing PCOS as relevant to healthy aging because it is associated with risks that may affect functional health, pregnancy health, and later cardiovascular trajectory. That makes early metabolic awareness relevant to present well-being without losing sight of future health.

Which core terms explain metabolic risk in PCOS?

Several terms make PCOS easier to understand. Metabolic syndrome (MetS) refers to a cluster of risk factors, usually including central adiposity, raised blood pressure, impaired fasting glucose, high triglycerides, and low high-density lipoprotein cholesterol (HDL-C). Human clinical studies report that MetS is more common in women with PCOS than in age-matched controls, although prevalence varies by population and criteria.

Homeostatic model assessment for insulin resistance (HOMA-IR) is a surrogate estimate of insulin resistance using fasting glucose and insulin. It is useful in research, but it is not the gold standard. The euglycaemic hyperinsulinaemic clamp is a more direct human research method for insulin sensitivity, though it is more complex. Sex hormone-binding globulin (SHBG) is a liver-produced protein that binds sex hormones. Lower SHBG is often associated with worse insulin-related metabolic status in PCOS.

Free androgen index (FAI) estimates biochemical androgen excess. Continuous metabolic syndrome severity z-score (cMetS z-score) is a research tool that tracks the severity of metabolic syndrome features over time rather than only classifying them as present or absent.

These terms matter for longevity because they help describe early metabolic stress before overt disease appears. They are markers of risk and pattern, not guarantees of future disease in any one person.

Who may benefit most from understanding this topic?

Several groups may benefit from understanding PCOS and metabolic health. First are adolescents and reproductive-age women with irregular cycles, hyperandrogenic features, or a known PCOS diagnosis. Human studies suggest metabolic risk can appear early, including in younger and non-obese women, so the topic is not limited to later adulthood or to people with obesity.

Second are women with PCOS who also have higher body mass index (BMI), larger waist circumference, elevated fasting glucose, or stronger biochemical hyperandrogenism. In a human long-term follow-up study, these factors were associated with later prediabetes risk. Women with abdominal obesity may carry greater metabolic burden than body weight alone suggests.

Third are people thinking across generations. A human systematic review and individual participant data meta-analysis found subtle cardiometabolic differences in offspring of women with PCOS, including lower birthweight and some altered metabolic markers, although several findings weakened after correction for multiple testing. This suggests concern is reasonable, but certainty is limited.

Finally, clinicians, public health planners, and families may benefit because PCOS sits at the intersection of endocrine, metabolic, and reproductive health. Understanding that overlap may support earlier recognition of risk patterns that influence healthy aging, even when symptoms seem mainly cosmetic or menstrual at first.

When and where is this knowledge most important?

This knowledge is most relevant at transition points across the lifespan. Adolescence matters because menstrual irregularity and androgen-related signs often begin then, yet metabolic risk may already be present. Early adulthood matters because weight gain, pregnancy planning, and emerging glucose changes can shift long-term risk. Midlife also matters, since human follow-up data suggest some women with PCOS develop worsening glucose handling and reduced beta-cell function over time.

It is especially important in contexts where metabolic load may rise. Examples include overweight or obesity, increasing waist circumference, family history of diabetes, prior gestational diabetes mellitus (GDM), or persistent hyperandrogenism. Research also highlights pregnancy as a meaningful context because maternal metabolic health may relate to offspring cardiometabolic patterns, though causal pathways remain under study.

Lifestyle context is another setting where this knowledge matters. In a human randomized controlled trial, a one-year program combining diet, exercise, and cognitive behavioural therapy (CBT) improved metabolic syndrome severity more than usual care in overweight or obese women with PCOS. That supports a practical principle: metabolic health in PCOS is modifiable to some extent, but effects vary by person and outcome.

In longevity terms, the best time to apply these principles is before complications become established, while avoiding the assumption that one marker or one phase of life tells the whole story.

Tell Me More

How do mood, stress, and behavior patterns affect PCOS metabolic aging?

Polycystic ovary syndrome (PCOS) does not affect metabolism in isolation. Scientific reviews describe higher rates of depression, anxiety, and body image distress in this condition, and these factors may indirectly shape eating patterns, sleep, activity, and treatment adherence. That matters for longevity because repeated behavioral strain can reinforce abdominal fat gain, blood pressure elevation, and poorer glucose regulation over time.

The strongest direct evidence here is mixed by outcome. In a one-year randomized controlled trial (in vivo human study) in women aged 18 to 38 years with body mass index (BMI) above 25 kilograms per square meter, a three-part program using cognitive behavioural therapy (CBT), diet, and exercise improved metabolic syndrome severity more than usual care. Outcomes were measured every three months, including systolic blood pressure, waist circumference, fasting insulin, and continuous metabolic syndrome severity z-score. The benefit appeared largely mediated by weight change, not by a proven direct effect of CBT alone.

This helps correct a common misunderstanding: metabolic care is not separate from psychological health. The evidence does not show that stress by itself causes PCOS, but it does suggest that behavior and mood may influence whether metabolic risk rises or falls across adult life.

Does PCOS risk change after midlife, or does it fade with age?

A common misconception is that polycystic ovary syndrome (PCOS) becomes irrelevant after fertility years. Available evidence does not support that simple view. Some reproductive features may soften with age, yet metabolic risk may persist or become more visible as aging, visceral fat gain, and hormonal change interact.

A long-term follow-up cohort (in vivo human study) tracked 31 women with prior PCOS for about 10 years, from a median age near 25.5 to 35 years. During follow-up, body mass index (BMI), waist circumference, and glucose values during oral glucose tolerance testing (OGTT) rose, while beta-cell function declined. By the later assessment, 45 percent had prediabetes, defined as impaired fasting glucose or impaired glucose tolerance. Insulin sensitivity measured by clamp-based methods changed little, which suggests that pancreatic reserve may weaken even when insulin resistance does not clearly worsen.

Menopause research also indicates that insulin resistance, hyperandrogenism, and visceral obesity can remain relevant after reproductive aging. The longevity link comes from cumulative exposure: glucose dysregulation, central fat gain, and vascular strain are established drivers of later cardiometabolic disease in the broader literature, even when direct lifespan trials in PCOS are limited.

Are all women with obesity and PCOS metabolically unhealthy?

No. Research suggests that obesity in polycystic ovary syndrome (PCOS) is metabolically diverse. A cross-sectional study (in vivo human study) of 94 treatment-naive women aged 18 to 30 years with PCOS and obesity separated participants into metabolically healthy obesity (MHO) and metabolically unhealthy obesity (MUO) using modified metabolic syndrome criteria. Women in the MUO group had higher insulin, higher high-sensitivity C-reactive protein (hs-CRP), worse lipid values, higher Visceral Adiposity Index (VAI), and higher Fatty Liver Index (FLI).

The caution is equally important: “metabolically healthy” does not mean risk-free or permanently protected. Cross-sectional data cannot show whether MHO remains stable over time, and other studies in the PCOS field suggest that metabolic status can deteriorate with aging or weight gain. In that same obesity phenotype study, lower adherence to the Mediterranean diet (MD) was associated with the MUO pattern, but this is an association, not proof that diet alone caused the difference.

For longevity, this means body weight alone may miss part of the picture. Fat distribution, inflammation, liver-related indices, and insulin dynamics may help explain why two people with similar body mass index (BMI) can have different long-term metabolic trajectories.

How should medication findings be viewed alongside lifestyle evidence?

Medication and lifestyle findings are often framed as competitors, but the evidence base presents them as addressing partly different problems. Reviews and guidelines describe metformin as an insulin-sensitizing drug that may improve insulin sensitivity and menstrual function, especially when impaired glucose tolerance or diabetes is present. Oral contraceptives can improve menstrual irregularity and androgen-related symptoms, but they are not metabolic treatments in the same sense.

For long-term metabolic outcomes, lifestyle evidence is currently more direct in this topic set. A randomized controlled trial (in vivo human study) reported changes from baseline to 12 months in metabolic syndrome prevalence, systolic blood pressure, and continuous metabolic syndrome severity z-score with a structured lifestyle program. By contrast, medication statements in the available reviews are mainly based on broader clinical literature or shorter-term outcomes, rather than long-duration trials designed around aging or hard cardiovascular endpoints.

This distinction matters for longevity. Symptom control may improve present quality of life, while metabolic risk reduction is usually inferred from effects on weight, glucose handling, blood pressure, and lipids. That inference is reasonable because those markers are linked with later disease in larger human populations, but direct proof of longer lifespan in PCOS-specific medication trials remains limited.

Level Up

Why does insulin signaling fail in PCOS?

Polycystic ovary syndrome (PCOS) is often described as a reproductive disorder, but its deeper biology involves altered nutrient sensing and insulin action. In vivo human studies, including long-term cohorts and systematic reviews, suggest that insulin resistance can be intrinsic to PCOS and not simply a result of higher body weight. That distinction matters for longevity because long exposure to inefficient insulin signaling may increase cumulative strain on blood vessels, pancreatic beta cells, and lipid handling.

Mechanistically, published evidence suggests defects may occur after the insulin receptor, meaning the hormone is present but the intracellular message is not fully transmitted. This can reduce glucose uptake in skeletal muscle and alter adipose tissue behavior. At the same time, insulin may still stimulate ovarian androgen production. This selective effect helps explain why hyperinsulinemia and hyperandrogenism often reinforce each other rather than act as separate problems. Lower sex hormone-binding globulin (SHBG) produced by the liver may further increase free androgen exposure.

The strongest support for this model comes from in vivo human studies using surrogate markers such as Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) and from smaller studies using the euglycaemic hyperinsulinaemic clamp, which is a more direct research measure of insulin sensitivity. The limitation is that these methods capture related but not identical features, and not all studies use the same phenotype definitions. Even so, the broader scientific literature supports the idea that PCOS may involve a selective insulin-signaling disturbance with long-term metabolic implications.

What drives metabolic decline beyond body weight?

Body weight matters in polycystic ovary syndrome (PCOS), but it does not explain the whole metabolic picture. In vivo human follow-up research suggests that some women with PCOS show worsening glucose regulation over time even when insulin sensitivity does not change greatly. In one long-term cohort, oral glucose tolerance test (OGTT) glucose values rose across roughly a decade, while beta-cell function declined. This pattern implies that pancreatic reserve may erode with age, making it harder to maintain normal glucose control under ongoing metabolic stress.

This helps refine a common oversimplification. Insulin resistance is often treated as the single driver, yet the evidence suggests a broader network involving beta-cell compensation, abdominal fat distribution, androgen exposure, inflammation, and liver-derived markers such as sex hormone-binding globulin (SHBG). In vivo human studies also show that baseline waist circumference, fasting and 120-minute glucose, triglycerides, and free androgen index (FAI) may help identify women more likely to develop prediabetes later.

Cross-sectional in vivo human studies on metabolically healthy obesity (MHO) and metabolically unhealthy obesity (MUO) add another layer. They suggest that women with similar body mass index (BMI) can have different inflammatory and metabolic profiles, including differences in high-sensitivity C-reactive protein (hs-CRP), Visceral Adiposity Index (VAI), and Fatty Liver Index (FLI). The longevity link is that aging risk may depend less on size alone and more on whether the system can preserve glucose control, vascular function, and metabolic flexibility across time.

Could PCOS shape health across generations?

An advanced question in this field is whether polycystic ovary syndrome (PCOS) affects not only the individual woman but also the metabolic trajectory of her children. The scientific rationale comes from developmental programming, which proposes that hormonal and metabolic conditions during fetal life may influence later physiology. In vivo human evidence from a systematic review with individual participant data suggests that offspring of women with PCOS may show subtle differences in cardiometabolic traits, including birthweight and some metabolic markers.

These findings deserve careful interpretation. The review reported signals that were modest and not uniformly robust after statistical correction. That means the evidence supports concern, but not certainty, about a distinct inherited or intrauterine metabolic pattern. Mechanistic explanations in the literature include exposure to maternal hyperinsulinemia, androgen excess, and altered placental environment during sensitive periods of development. However, those pathways remain partly inferential in humans.

Animal and experimental models are often used to test fetal androgen exposure more directly, but those findings should not be treated as direct proof in people. Species differences, controlled exposures, and short timelines limit how far they can be generalized. For longevity, the broader implication is still important: PCOS may be part of a life-course biology in which metabolic health before and during pregnancy could influence future risk patterns in the next generation, even though the size and persistence of that effect remain unsettled.

How might PCOS care change over the next decade?

Future progress will likely come less from finding one universal marker and more from mapping subtypes of risk across the lifespan. Current in vivo human studies already suggest that polycystic ovary syndrome (PCOS) is metabolically heterogeneous. Some women mainly show androgen-related features, while others show stronger glucose, inflammatory, or liver-related abnormalities. Research is moving toward composite measures that capture this variation more precisely than a simple yes-or-no diagnosis.

One example is the continuous metabolic syndrome severity z-score (cMetS z-score), used in an in vivo human randomized trial to track metabolic change over 12 months. This kind of score may prove useful because it follows severity over time rather than only counting whether a threshold has been crossed. Other candidate tools in the literature include sex hormone-binding globulin (SHBG), phase angle from body composition analysis, and indices such as Visceral Adiposity Index (VAI) or Fatty Liver Index (FLI). These are promising for stratification, but they are not yet established longevity markers.

Over the next decade, available evidence may support a more life-course framework: earlier metabolic phenotyping, better separation of mechanistic risk from proven outcomes, and stronger links between reproductive events and later cardiometabolic aging. The main caution is that many newer markers are supported by associative human data, not long-term trials with hard outcomes such as myocardial infarction, stroke, or mortality. For that reason, future best practice will likely depend on combining established metabolic measures with more refined phenotype tracking, rather than replacing one with the other.

Pros and Cons

Pros

• Lifestyle is first-line
  In vivo human RCT and guideline-based reviews suggest structured diet, exercise, and CBT may improve metabolic syndrome severity in overweight or obese women with PCOS, linking present symptom relief with lower long-term cardiometabolic strain.

• Modest weight loss helps
  In vivo human studies report that about 5–10% weight loss is associated with better insulin, androgen, lipid, and menstrual measures. Benefits appear strongest in women with overweight or abdominal adiposity, both relevant to healthy aging.

• Exercise aids metabolism
  In vivo human evidence suggests physical activity may raise SHBG and improve insulin sensitivity, blood pressure, lipids, mood, and body image. This offers both metabolic and behavioral gains that may support sustained risk reduction over time.

• Early risk can be tracked
  In vivo human cohort studies suggest markers such as waist circumference, fasting glucose, SHBG, and free androgen index may help identify women at higher risk for prediabetes. Earlier tracking may support prevention before overt disease develops.

• Metformin has a role
  Clinical studies and reviews suggest metformin may improve insulin sensitivity and menstrual function, especially when impaired glucose tolerance or diabetes is present. Its value appears more targeted than universal, but it may support long-term metabolic care.

Cons

• Risk persists over time
  Long-term in vivo human cohort data suggest glucose handling may worsen with age in some women with PCOS, with declining beta-cell function and substantial prediabetes incidence. This means metabolic burden may remain relevant beyond fertility years.

• Obesity worsens burden
  Human cohort and review evidence suggests higher BMI and waist circumference are associated with greater insulin resistance, dysglycemia, and metabolic syndrome burden. The risk appears higher in overweight or obese phenotypes, though not limited to them.

• Cardiometabolic rates are high
  Systematic reviews and large human studies suggest PCOS is associated with higher rates of impaired glucose tolerance, type 2 diabetes, hypertension, dyslipidemia, and metabolic syndrome. These patterns may weigh on long-term cardiovascular aging.

• Not all benefits are proven
  Human trials and reviews indicate some expected gains remain uncertain. Low-glycemic diets show subtle or inconclusive effects, and some trials found no clear menstrual advantage of pharmacotherapy over lifestyle intervention alone.

• Mental health can interfere
  Human observational evidence suggests depression, anxiety, and body image distress are more common in PCOS. These factors may reduce adherence to diet, activity, and follow-up, indirectly limiting metabolic improvement across the lifespan.

Considerations

• PCOS is heterogeneous
  Human studies show metabolic risk varies by phenotype, age, adiposity, and androgen status. Lean women may still have insulin resistance, while not all women with obesity show the same metabolic pattern. One profile should not define all PCOS.

• Evidence differs by outcome
  Some findings come from randomized in vivo human trials, while others rely on cohorts, systematic reviews, or mechanistic reasoning. Confidence is stronger for metabolic markers than for hard outcomes such as myocardial infarction, stroke, or mortality.

• Short vs long term
  Human trials suggest 12-month lifestyle programs can improve metabolic measures, but long-term maintenance is less certain. Cohort data also suggest risk can re-emerge or progress, so short-term response may not fully predict aging trajectory.

• Monitoring matters
  Available human evidence supports repeated assessment of blood pressure, glycemic status, waist circumference, and related markers across adult life. This is especially relevant when BMI, fasting glucose, or hyperandrogenism are already elevated.

• Pregnancy adds context  
  Human studies suggest PCOS is linked with gestational diabetes and hypertensive pregnancy complications, and offspring research shows possible cardiometabolic differences. These intergenerational signals are important, but the causal pathways remain unsettled.

Actionable Intelligence

Innovative Tips

• ‍cMetS Score Tracking
  Human RCT: track cMetS-like markers q3mo for 12 mo; exploratory, not a clinical standard.‍

• SHBG Trend Review
  Human cohort: review SHBG with labs yearly; may refine risk context, early evidence only.
  ‍
• FAI Pattern Watch
  Human cohort: recheck FAI over 6-12 mo; higher values were linked with later dysglycemia.
  ‍
• OGTT Timing Check
  Human cohort: OGTT every 1-3 y was studied in higher-risk PCOS; discuss timing with a clinician.
  ‍
• Waist-First Tracking
  Human cohort: log waist monthly for 6-12 mo; central gain may flag metabolic drift earlier.‍
  ‍
• ‍CBT Plus Exercise
  Human RCT: 12-mo CBT+diet+exercise improved MetS severity; effect varied with weight change.
  ‍
• ‍Mediterranean Pattern
  Human studies examined Mediterranean-style eating most days for months; diet-specific gains vary.
  ‍
• Vitamin D Context
  Human review: if deficient, repletion may help; benefit beyond deficiency remains uncertain.
  ‍
• Inositol Caution
  Mechanistic/human review: inositols are studied over months; long-term outcome proof is limited.
  ‍
• Offspring Risk Lens
  Human meta-analysis: preconception metabolic review may matter; child benefits are not established.

Convergent and Divergent Viewpoints

Convergents

• PCOS carries durable metabolic relevance across adulthood
  In vivo human cohort and reviews agree PCOS remains metabolically relevant beyond fertility years, with implications for healthy aging and later cardiometabolic burden.

• Glucose dysregulation risk is consistently elevated
  Systematic reviews and in vivo human cohorts agree PCOS is associated with higher prediabetes and type 2 diabetes risk, especially with aging or excess adiposity.

• Abdominal adiposity strengthens long-term risk
  In vivo human evidence agrees higher BMI and waist measures are linked with worse metabolic trajectory in PCOS, including later dysglycemia and vascular strain.

• Beta-cell reserve may decline with age in PCOS
  Long-term in vivo human follow-up supports age-related decline in beta-cell function in PCOS, a pattern relevant to future glucose control and longevity.

• Insulin resistance is a central mechanistic feature
  Human studies and clinical reviews agree insulin resistance often underlies metabolic and androgen-related abnormalities, though its severity varies by phenotype.

• PCOS is metabolically heterogeneous
  Human studies agree metabolic burden differs by phenotype, adiposity, androgen profile, and life stage; one risk pattern does not fit all women.

• Lifestyle intervention is the main metabolic strategy
  In vivo human RCTs and guideline-based reviews agree diet, exercise, and behavior support can improve metabolic markers, especially in overweight or obese PCOS.

• Weight reduction of about 5–10% is meaningful
  Human trial and review evidence agree modest weight loss is associated with better insulin, androgen, and metabolic syndrome measures in higher-adiposity PCOS.

• Risk tracking should extend beyond body weight alone
  Human evidence agrees waist, glucose indices, SHBG, FAI, and related markers may refine risk context better than BMI alone for long-term metabolic follow-up.

• Intergenerational signals merit attention, not certainty
  Human IPD meta-analysis supports subtle offspring cardiometabolic differences in PCOS pregnancies, but effects appear modest and not uniformly robust after correction.

Divergent

• Does insulin sensitivity worsen with age, or mainly beta-cell reserve?
  Some researchers say aging in PCOS mainly reduces beta-cell function, while others argue worsening insulin resistance also contributes; methods differ across clamp and surrogate studies.

• How much cardiovascular event risk is truly increased?
  Some researchers argue PCOS clearly raises later vascular event risk, while others say hard outcomes remain inconsistent after accounting for obesity, age, and study design.

• Is metabolically healthy obesity a stable PCOS phenotype?
  Some researchers say MHO in PCOS marks a distinct lower-risk subgroup; others say it may be temporary and can shift toward MUO with age or weight gain.

• Which diet pattern matters most beyond weight loss?
  Some researchers favor Mediterranean-style patterns; others emphasize lower-glycemic or lower-carbohydrate approaches. Comparative human outcome data remain limited and heterogeneous.

• How strong is metformin’s role for long-term aging risk?
  Some researchers support earlier metformin for insulin-related risk; others reserve it for impaired glucose tolerance or diabetes, citing stronger lifestyle-first evidence.

• Should SHBG and FAI be used routinely for metabolic stratification?
  Some researchers view SHBG and FAI as useful early risk markers; others see them as supportive but insufficiently standardized for broad metabolic decision-making.

• How often should OGTT-based screening be used?
  Some researchers favor more frequent OGTT in higher-risk PCOS, while others prefer selective use because burdens, thresholds, and incremental value differ by setting.

• Are offspring effects mainly intrauterine or genetic?
  Some researchers attribute offspring findings to maternal pregnancy environment; others argue shared genetics and family lifestyle may explain much of the observed signal.

• Does menopause attenuate or preserve PCOS-related metabolic risk?
  Some researchers say reproductive features soften after menopause, reducing distinct PCOS impact; others argue insulin resistance and visceral adiposity keep risk clinically relevant.

Definition

• Polycystic ovary syndrome (PCOS)
  A common endocrine condition that combines reproductive signs with metabolic changes.

• Endocrine
  Relating to hormones and the glands that make them.

• Metabolic health
  How the body handles glucose, insulin, blood lipids, blood pressure, and body fat distribution.

• Systematic review
  A study that collects and evaluates all relevant research on a question using a structured method.

• Meta-analysis
  A statistical method that combines results from multiple studies to estimate an overall effect.

• Longitudinal study
  A study that follows the same people over time to see how outcomes change.

• Heterogeneous
  Not the same in every person; in PCOS, one person may have marked hyperandrogenism, while another may show milder reproductive signs but more metabolic burden.

• Hyperandrogenism (HA)
  Excess androgen activity, measured clinically or biochemically.

• Androgen
  A group of hormones that influence male-type traits but are also normally present in women.

• Biochemically
  Measured through laboratory testing of body fluids such as blood.

• Insulin resistance (IR)
  Body tissues respond less effectively to insulin.

• Hyperinsulinemia
  Higher-than-normal levels of insulin in the blood.

• Dyslipidemia
  An unfavorable lipid pattern, often involving triglycerides and high-density lipoprotein cholesterol (HDL-C).

• Triglycerides
  A type of fat in the blood that is commonly measured as part of metabolic risk.

• High-density lipoprotein cholesterol (HDL-C)
  Often called “good” cholesterol; lower levels are part of an unfavorable metabolic pattern.

• Hypertension
  Persistently elevated blood pressure.

• Type 2 diabetes
  A long-term condition in which the body cannot regulate blood glucose normally, often involving insulin resistance and reduced insulin effectiveness.

• Cerebrovascular events
  Problems caused by disrupted blood flow in the brain, such as stroke.

• Coronary events
  Problems involving blood flow to the heart, such as heart attack.

• Cardiovascular disease
  Disease involving the heart and blood vessels.

• Cardiometabolic health
  The combined state of metabolic and cardiovascular health, including glucose control, blood pressure, blood lipids, and body fat distribution.

• Glucose dysregulation
  Abnormal control of blood glucose levels.

• Abdominal adiposity
  Excess fat stored around the abdomen.

• Visceral fat
  Fat stored around internal organs in the abdomen, often linked to higher metabolic risk.

• Vascular stress
  Strain or damage affecting blood vessels over time.

• Glucose concentrations
  The amount of glucose present in the blood.

• Beta-cell function
  How well the pancreatic beta cells produce and release insulin.

• Insulin sensitivity
  How effectively the body responds to insulin.

• Metabolic reserve
  The body’s capacity to maintain normal metabolic function under stress or over time.

• Metabolic syndrome (MetS)
  A cluster of risk factors, usually including central adiposity, raised blood pressure, impaired fasting glucose, high triglycerides, and low high-density lipoprotein cholesterol (HDL-C).

• Central adiposity
  Excess fat concentrated around the waist or abdomen.

• Impaired fasting glucose
  Fasting blood glucose that is higher than normal but not high enough for diabetes.

• Homeostatic model assessment for insulin resistance (HOMA-IR)
  A surrogate estimate of insulin resistance using fasting glucose and insulin.

• Surrogate estimate
  An indirect measure used to estimate something that is harder to measure directly.

• Gold standard 
  The best available method against which other methods are compared.

• Euglycaemic hyperinsulinaemic clamp
  A more direct human research method for insulin sensitivity, though it is more complex.

• Sex hormone-binding globulin (SHBG)
  A liver-produced protein that binds sex hormones. Lower SHBG is often associated with worse insulin-related metabolic status in PCOS.

• Free androgen index (FAI)
  Estimates biochemical androgen excess.

• Biochemical androgen excess
  Higher-than-normal androgen exposure identified through blood testing.

• Continuous metabolic syndrome severity z-score (cMetS z-score)
  A research tool that tracks the severity of metabolic syndrome features over time rather than only classifying them as present or absent.

• Prediabetes
  Blood glucose levels that are above normal but below the threshold for diabetes.

• Birthweight
  The weight of a baby at birth; in this context it is discussed as a possible offspring cardiometabolic marker.

• Individual participant data meta-analysis
  A meta-analysis that combines raw data from individual participants across studies rather than only published summary results.

• Correction for multiple testing
  A statistical adjustment used when many comparisons are tested, to reduce the chance of false-positive findings.

• Gestational diabetes mellitus (GDM)
  Diabetes or high blood glucose first recognized during pregnancy.

• Randomized controlled trial
  A study in which participants are randomly assigned to different interventions so outcomes can be compared more reliably.

• Cognitive behavioural therapy (CBT)
  A skills-based psychological treatment approach that helps change thought and behavior patterns.

• In vivo human study
  Research performed in living human participants.

• Systolic blood pressure
  The top number in a blood pressure reading, reflecting pressure when the heart contracts.

• Body mass index (BMI)
  A measure that relates body weight to height.

• Oral glucose tolerance test (OGTT)
  A test that measures how the body handles glucose over time after a glucose drink.

• Impaired glucose tolerance
  Higher-than-normal blood glucose after a glucose challenge, but not high enough for diabetes.

• Menopause
  The life stage after menstrual periods stop permanently.

• Reproductive aging
  The hormonal and biological changes that occur as reproductive function declines with age.

• Cross-sectional study
  A study that looks at participants at one point in time rather than following them over time.

• Treatment-naive
  Not previously treated for the condition being studied.

• Metabolically healthy obesity (MHO)
  An obesity pattern in which a person has obesity by body size criteria but shows a lower-risk metabolic profile.

• Metabolically unhealthy obesity (MUO)
  An obesity pattern associated with worse metabolic abnormalities such as higher insulin, inflammation, and worse lipid values.

• High-sensitivity C-reactive protein (hs-CRP)
  A blood marker of low-grade inflammation.

• Visceral Adiposity Index (VAI)
  An index intended to reflect visceral fat-related metabolic risk.

• Fatty Liver Index (FLI)
  An index used to estimate the likelihood of fatty liver-related metabolic burden.

• Mediterranean diet (MD)
  A dietary pattern centered around Mediterranean-style eating, discussed in the literature as linked with better metabolic health in PCOS.

• Inflammation
  Activation of the immune system that can become chronically elevated and contribute to metabolic risk.

• Metformin
  An insulin-sensitizing drug that may improve insulin sensitivity and menstrual function, especially when impaired glucose tolerance or diabetes is present.

• Insulin-sensitizing drug
  A medication that helps the body respond better to insulin.

• Oral contraceptives
  Hormonal medications used to improve menstrual irregularity and androgen-related symptoms.

• Hard cardiovascular endpoints
  Major clinical outcomes such as myocardial infarction, stroke, or death, rather than changes in risk markers alone.

• Nutrient sensing
  How cells detect and respond to the availability of energy and nutrients.

• Insulin signaling
  The chain of events inside cells that happens after insulin binds to its receptor.

• Intrinsic
  Part of the condition itself rather than caused only by another factor such as body weight.

• Insulin receptor
  A protein on the cell surface that binds insulin and starts insulin signaling.

• Intracellular message
  The signal passed inside a cell after a receptor is activated.

• Glucose uptake
  The process by which cells take in glucose from the blood.

• Skeletal muscle
  Muscle attached to bones; it is a major tissue involved in glucose uptake.

• Adipose tissue
  Body fat tissue.

• Ovarian androgen production
  Production of androgen hormones by the ovaries.

• Selective insulin-signaling disturbance
  A pattern in which some insulin actions are impaired while others remain active.

• Pancreatic reserve
  The capacity of the pancreas, especially beta cells, to keep producing enough insulin over time.

• Metabolic flexibility
  The body’s ability to adapt fuel use and maintain stable metabolism under changing conditions.

• Developmental programming
  The idea that conditions during fetal life may influence health and physiology later in life.

• Intrauterine
  Occurring within the uterus during pregnancy.

• Placental environment
  The hormonal and metabolic conditions created by the placenta during pregnancy.

• Fetal androgen exposure
  Exposure of a developing fetus to androgen hormones.

• Phenotyping
  Detailed characterization of a person’s traits or disease pattern.

• Composite measures
  Scores built from multiple variables to capture a broader pattern of risk or disease severity.

• Phase angle
  A body composition analysis measure discussed as a possible future stratification tool.

• Stratification
  Grouping people by risk or subtype to guide understanding or management.

• Myocardial infarction
  Heart attack; damage to heart muscle caused by reduced blood flow.

• Mortality
  Death as an outcome measure in research.

• Dysglycemia
  Abnormal blood glucose regulation, including prediabetes or diabetes.

• Atherogenic lipoprotein profile
  A blood lipid pattern associated with increased risk of plaque buildup in arteries.

• Oligomenorrhoea
  Infrequent menstrual periods.

• Oligo/anovulatory cycles
  Menstrual cycles with infrequent ovulation or no ovulation.

• Hirsutism
  Excess growth of coarse hair in a male-pattern distribution in women, often related to androgen excess.

• Rotterdam consensus
  A commonly used set of diagnostic criteria for PCOS.

• Androgen Excess Society (AES)
  A professional society associated with another set of diagnostic criteria for PCOS.

• Ultrasonographic criteria
  Diagnosis-related features identified using ultrasound imaging.

• Ferriman-Gallwey score
  A clinical scoring system used to assess hirsutism.

• Folliculogenesis
  The development of ovarian follicles.

• Gonadotropin secretion
  Release of hormones such as luteinizing hormone and follicle-stimulating hormone that regulate reproduction.

• Epigenetic contributions
  Changes in gene regulation that do not alter the DNA sequence itself but may influence disease risk or traits.

• Follicular fluid
  Fluid surrounding the developing egg within an ovarian follicle.

• Perimenopause
  The transition period leading up to menopause.

• Endometrial pathology
  Disease affecting the lining of the uterus.

• Medical nutrition therapy
  Structured dietary care delivered as part of clinical treatment.

• Low-glycemic diet
  A diet designed to reduce blood glucose spikes after meals, though effects were described as subtle or inconclusive in the provided context.

• Vitamin D deficiency
  Lower-than-normal vitamin D status.

• Clomiphene citrate
  A medication used to induce ovulation.

• Ovulation induction
  Treatment intended to trigger ovulation.